PushMed is a pioneering and dynamic high-tech medical device enterprise that was established in January 2012, with its headquarters situated in Shanghai. We specialize in the cutting-edge field of cardiovascular and cerebrovascular interventional medical devices, encompassing research, development, manufacturing, and sales. At PushMed, our unwavering commitment to technological innovation has paved the way for breakthrough solutions in the diagnosis and treatment of cardiac conditions.
With a strategic focus on the development of comprehensive structural heart disease intervention devices and neurovascular intervention devices, PushMed has emerged as a frontrunner in China’s thriving cardiac intervention medical device sector. Our steadfast pursuit of excellence has propelled us to the forefront of the industry, positioning PushMed as a trusted partner for healthcare providers and a symbol of pioneering advancements.
At the core of our product portfolio lie our flagship offerings, the state-of-the-art Left Atrial Appendage Closure System and a comprehensive range of congenital heart disease interventions. These innovative solutions have garnered widespread acclaim within the medical community, exemplifying PushMed’s dedication to revolutionizing patient care.
PushMed’s commitment to quality and regulatory compliance is underscored by our impressive track record. In 2022 alone, we achieved the significant milestone of obtaining three Class III Medical Device Registration Certificates, including the highly coveted approvals for our Atrial Septal Puncture System, Left Atrial Guide Wires, and Cardiac Closure Device Delivery System. These accomplishments not only solidify our market position but also testify to our unwavering commitment to delivering superior products that meet the stringent standards of global healthcare regulatory authorities.
Driven by a culture of innovation and an unwavering focus on research and development, PushMed boasts a robust pipeline of cutting-edge products. Among these are the transcatheter mitral valve clip and delivery system, a groundbreaking solution poised to revolutionize the treatment of mitral valve disorders. Furthermore, our pioneering patent foramen ovale closure device and pulse ablation system exemplify our relentless pursuit of breakthroughs in the field of cardiovascular and cerebrovascular intervention.
At PushMed, we recognize that intellectual property is the lifeblood of innovation. Our steadfast commitment to protecting our intellectual assets has resulted in the acquisition of numerous authorized invention patents, including prestigious grants in the United States and Europe. With 14 authorized invention patents and 26 utility model patents, PushMed’s intellectual property portfolio stands as a testament to our unwavering dedication to pioneering advancements.
We take immense pride in our comprehensive business ecosystem, encompassing robust procurement, state-of-the-art manufacturing facilities, a dynamic sales network, and a customer-centric service system. Our extensive network of over 250 trusted distributors spans the nation, ensuring that our innovative products reach healthcare professionals and patients across a diverse range of medical institutions. Notably, our products have gained widespread acceptance, with inclusion in the medical insurance systems of 29 provinces and cities nationwide.
As a dominant force in Shanghai’s medical landscape, PushMed has achieved an impressive market share of over 70% in key regions with concentrated medical resources. This extraordinary market penetration reflects the trust placed in our brand, as well as our ability to deliver innovative solutions that address the evolving needs of healthcare providers.
PushMed’s unwavering commitment to excellence, innovation, and patient-centricity has solidified our position as a respected leader in the cardiovascular and cerebrovascular interventional medical device sector. As we continue to push boundaries and explore new frontiers, we remain steadfast in our mission to transform healthcare and improve patient outcomes through groundbreaking advancements in medical technology.
